Format

Send to

Choose Destination
Cancer Discov. 2016 Jan;6(1):20-1. doi: 10.1158/2159-8290.CD-15-1411.

Targeting ALK: The Ten Lives of a Tumor.

Author information

1
Department of Oncogenomics, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands. r.versteeg@amc.nl Rani_George@DFCI.Harvard.edu.
2
Department of Pediatric Hematology and Oncology, Dana-Farber Cancer Institute and Boston Children's Hospital, Harvard Medical School, Boston, Massachusetts. r.versteeg@amc.nl Rani_George@DFCI.Harvard.edu.

Abstract

In this issue, Infarinato and colleagues report the results of preclinical testing of a novel ALK/ROS1 inhibitor, PF-06463922, in neuroblastoma. This small-molecule inhibitor was shown to efficiently inhibit the growth of patient-derived and established neuroblastoma xenograft models expressing mutated ALK. Although the in vivo data are impressive and the authors suggest that clinical trials are warranted, the presented data also suggest that it is as yet too early to welcome the new drug as a magic bullet.

PMID:
26747894
PMCID:
PMC4709027
DOI:
10.1158/2159-8290.CD-15-1411
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for HighWire Icon for PubMed Central
Loading ...
Support Center